Retatrutide results: every published trial number in one table. | Reddit

Five human studies with published outcomes make up the record: the phase 2 obesity trial, the phase 2 type 2 diabetes trial, a liver-fat substudy, a body-composition substudy, and one phase 3 readout. The table below holds every headline number, each tied to its study, population, duration and arm. The sections after it unpack each row, and a separate list covers what the results do not show yet.

The 48-week phase 2 obesity trial in the New England Journal of Medicine is the source of the numbers that made the compound famous. It randomised 338 adults to once-weekly retatrutide or placebo, with the dosing arms described in our companion piece on how the retatrutide injection was dosed and titrated.

The dose response was visible at both published timepoints. At 24 weeks the 8 mg and 12 mg arms were nearly level, at 17.3% and 17.5% mean reduction. By 48 weeks they had separated to 22.8% and 24.2%, which is the pattern of an effect still accumulating late in the trial rather than one that plateaued early.

The 2023 Lancet phase 2 trial randomised 281 adults with type 2 diabetes across placebo, dulaglutide 1.5 mg and six retatrutide arms. At 24 weeks, HbA1c fell by 0.43 percentage points in the lowest retatrutide arm (0.5 mg) and by 2.02 points in the 12 mg arm, against 0.01 points with placebo and 1.41 points with dulaglutide. The abstract notes the findings were consistent at 36 weeks.

Bodyweight decreased dose dependently at 36 weeks, reaching 16.94% in the 12 mg arm versus 3.00% with placebo and 2.02% with dulaglutide. The trial reported no severe hypoglycaemia and no deaths during the study.

A phase 2a substudy published in Nature Medicine in 2024 followed 98 participants with metabolic dysfunction-associated steatotic liver disease, drawn from the obesity trial, with liver fat measured by imaging. At 24 weeks, mean relative liver fat changed by -42.9% at 1 mg, -57.0% at 4 mg, -81.4% at 8 mg and -82.4% at 12 mg, versus +0.3% with placebo.

The substudy also reported how many participants reached normal liver fat, defined as under 5%: 27% at 1 mg, 52% at 4 mg, 79% at 8 mg and 86% at 12 mg, versus 0% with placebo, all at 24 weeks. The abstract does not state 48-week liver-fat figures, so none are given here.

A substudy of the diabetes trial, published in The Lancet Diabetes & Endocrinology in 2025, enrolled 189 participants and used DXA scans to ask what the lost weight was made of. At week 36, total body fat mass was reduced 26.1% in the pooled 8 mg group and 23.2% in the 12 mg group; the 8 mg difference versus placebo was a least-squares mean of -21.6 (95% CI -27.1 to -16.1).

On the question most searchers bring to this page, the abstract offers one sentence: the proportion of lean mass loss to weight loss was similar to other obesity treatments.

This is the first registrational readout, published in The Lancet in 2026: a 40-week, randomised, double-blind, placebo-controlled trial at 48 sites in the USA, Mexico and India, in 537 adults whose type 2 diabetes was not controlled by diet and exercise alone. Retatrutide ran as monotherapy at 4, 9 or 12 mg once weekly.

HbA1c fell 1.69, 1.86 and 1.94 percentage points across the three doses, versus 0.81 with placebo. Bodyweight fell 11.5%, 13.9% and 15.3%, versus 2.6% with placebo. The abstract describes mostly mild-to-moderate gastrointestinal adverse events that subsided over time, discontinuations due to adverse events of 2 to 5% versus 0% with placebo, no severe hypoglycaemia, and two deaths in the 4 mg group described as unrelated to the study drug.

The 24.2% figure and the 15.3% figure come from different trials that differ in almost every dimension: population (obesity without diabetes versus type 2 diabetes), duration (48 versus 40 weeks), phase, sites and arms. The published reports do not explain the gap, and this page will not supply a mechanism they do not.

What the record supports saying is narrower: quoting the 24.2% obesity figure as the expected result in a diabetes population contradicts the published phase 3 data, and quoting either as a personal projection contradicts what a group mean is.

Most people searching this query have already watched a video. Two widely shared ones, with a combined audience in the hundreds of thousands, call retatrutide the “god molecule” and “the 24% weight loss drug,” describe the liver effect as power washing the organ from the inside out, and attach numbers to claims the published abstracts do not carry. The claims are listed below against the record, labelled as claims.

The published answer is thinner than the online debate. The body-composition substudy is the only retatrutide trial to publish a lean-mass finding, and its abstract says the proportion of lean mass loss to weight loss was similar to other obesity treatments. It does not state the 40% figure that circulates in videos, and neither does any other abstract cited here.

The class-level context comes from a 2024 narrative review in Diabetes Care, which examines lean-mass loss across incretin-based weight-loss drugs, names retatrutide among them, and argues for resistance exercise as the practical countermeasure during treatment.

A results page is honest only if it states the edges of the record. Everything below is absent from the trial reports cited on this page, which is different from being disproven: these are the questions the ongoing registrational program and future studies exist to answer.

No. Every figure on this page is a group mean from a selected population: screened adults who met eligibility criteria, received a verified product, titrated on a protocol and attended monitoring visits. A mean says nothing about the spread around it, and the abstracts cited here do not publish responder-level distributions.

That cuts in both directions. Some participants lost more than the mean, some lost less, and the numbers say nothing at all about someone outside the eligibility criteria, on a different schedule, or injecting material no trial tested.

The results were produced inside trials, with a defined product and monitoring, and retatrutide remains investigational: the lawful way to receive it is enrolment in the registrational program, as our retatrutide overview explains in detail. Nothing about the trial numbers transfers to an unverified vial from an unregulated seller.

If the underlying goal is weight and metabolic health support now, semaglutide and tirzepatide have approved products behind them and an established prescribing route, and a clinician decides whether either fits your history. Every dose PepScribe dispenses is compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain. The online visit is free, and you pay only if a clinician prescribes.